Key takeaways
- The company trading as LSE:IBAI is Imaging Biometrics Limited, a Jersey-incorporated business on the London Stock Exchange's Main Market; it was renamed from IQ-AI Limited (LSE:IQAI) in 2025 and traces back to the former Flying Brands shell.
- Its core commercial product is IB Neuro, MRI post-processing software that measures cerebral blood volume to help assess brain-tumour treatment response; sister assets include Stone Checker (kidney-stone software) and Kirkstall (Quasi Vivo organ-on-a-chip systems).
- In 2026 the group highlighted the ECOG-ACRIN EAF151 Phase II results at ASCO showing its standardised relative cerebral blood volume metric had the strongest statistically significant association with overall survival in recurrent glioblastoma.
- The company also reported positive first-in-human Phase 1 data for oral gallium maltolate and reopened an Expanded Access Programme, after earlier signalling it would deprioritise the drug to focus on imaging.
- This is an early-stage, loss-making micro-cap: reported trailing revenue was under £0.8m with a net loss, a market value of roughly £1.5m-£2m and, on third-party estimates, limited cash runway, so dilution and funding risk are central to the story.
An Identity Worth Checking First
The business trading under LSE:IBAI is Imaging Biometrics Limited, a company registered in Jersey and listed on the Main Market of the London Stock Exchange. It's not a newly floated venture — it was known until 2025 as IQ-AI Limited, ticker IQAI, and further back its listing vehicle was the old Flying Brands consumer group. Anyone researching the name should expect to find a long paper trail under more than one identity, and some legacy data services still cross-reference the older names.
What Imaging Biometrics does today sits at the intersection of two heavily discussed themes in modern healthcare: artificial intelligence and quantitative analytics applied to medical imaging, and the desperate search for better treatments in aggressive brain cancer. Those are genuine, large markets. The company, however, is a very small participant in them, and the gap between the size of the opportunity and the size of the enterprise is the single most important fact to hold in mind.
A Small Holding Company With Three Distinct Assets
Imaging Biometrics Limited is the London-listed holding company for a small group of healthcare technology assets, most centred on the United States. Its principal operating subsidiary is Imaging Biometrics LLC, a Wisconsin-based developer of neuroimaging software acquired in 2018, during the period when the listed entity was still trading as IQ-AI.
The corporate structure spans three broad activities. The largest by revenue is medical imaging software, delivered through the Imaging Biometrics LLC platform. Alongside this sits Stone Checker Software, a smaller business applying image analysis to kidney-stone assessment, and Kirkstall Limited, a UK company that makes Quasi Vivo organ-on-a-chip cell-culture systems used in laboratory research. The group also controls the rights to an investigational drug, oral gallium maltolate, aimed at glioblastoma. Trevor Brown has been chief executive and chairman since 2015 — a combination of roles worth flagging on governance grounds. Employee numbers are tiny, with third-party profiles putting headcount at around seven.
IB Neuro: Measuring What the Eye Can't See
The commercial heart of the group is IB Neuro, a suite of software tools that post-process magnetic resonance imaging (MRI) scans of the brain. Its distinctive capability is measurement of cerebral blood volume from dynamic susceptibility contrast MRI, and in particular a standardised, reproducible version of relative cerebral blood volume. Tumours tend to recruit abnormal blood supply, so changes in this measure can, in principle, signal whether a therapy is working sooner than tumour size alone would reveal.
The business model here is closer to specialist scientific software and services than to a consumer app. Customers include research hospitals, clinical-trial sites, contract research organisations, and pharmaceutical sponsors running trials of anti-angiogenic and other brain-cancer therapies. The second technology strand is Kirkstall's Quasi Vivo platform, organ-on-a-chip systems that attempt to recreate how human tissues and fluids interact in a microfluidic device — aligned with a strong regulatory and ethical tailwind towards reducing animal testing. The third strand, gallium maltolate, is a pharmaceutical asset with binary clinical and regulatory outcomes rather than incremental software revenue.
The ASCO Validation That Actually Matters
The most substantive news of 2026 concerned clinical validation of the imaging technology. In late May, results of the EAF151 study were presented at the American Society of Clinical Oncology (ASCO) annual meeting. EAF151 was a prospective, multi-centre Phase II trial sponsored by the ECOG-ACRIN Cancer Research Group, spanning dozens of centres and around 146 patients, evaluating DSC-MRI-derived cerebral blood volume for assessing response to bevacizumab in recurrent glioblastoma.
According to the company's announcement, the standardised relative cerebral blood volume metric produced using IB Neuro showed the strongest statistically significant association with overall survival among the imaging approaches examined, outperforming manually normalised methods. In a follow-up regulatory statement in early June, the group set out a commercialisation and revenue path built around this evidence, targeting trial sites, sponsors, and contract research organisations, stressing it intended to pursue incremental revenue without material external funding.
An Unexpected Drug Programme Restart
In June, the company reported positive first-in-human Phase 1 data for oral gallium maltolate in recurrent or treatment-refractory glioblastoma, describing the compound as tolerated up to a high daily dose, identifying a recommended Phase 2 dose, and citing a median overall survival figure presented as encouraging against historical benchmarks. On that basis, it said it would reopen an Expanded Access Programme to a limited number of additional eligible patients — a notable shift, because earlier commentary had suggested the company was drawing a line under the drug to concentrate on imaging.
Separately, in May, the group's Kirkstall subsidiary was selected as an industry partner in a UK research project to build a living glioblastoma 'tumour on a chip' model, working with Nottingham Trent University and supported through a grant scheme run jointly by the Biotechnology and Biological Sciences Research Council and the National Centre for the Replacement, Refinement and Reduction of Animals in Research. Management framed the award as validation of the Kirkstall acquisition rather than as a material near-term revenue event.
The Financial Reality Behind the Science
Imaging Biometrics is a loss-making micro-cap. Third-party financial databases reported trailing revenue of a little under £0.8m and a net loss in the region of £0.4m, against a market capitalisation of roughly £1.5m to £2m. These are aggregator figures rather than audited primary numbers, but the order of magnitude is clear and consistent across sources.
The revenue is genuine, which distinguishes Imaging Biometrics from a pure pre-revenue concept stock. The great majority of income came from medical software, with smaller contributions from gallium-maltolate-related activity and a very small amount from the organ-on-a-chip business, with the overwhelming majority generated in the United States. That said, revenue at this level barely covers the cost base of even a seven-person group with clinical and regulatory commitments, which is why the company continues to report losses. One widely cited third-party assessment flagged that, on its estimate of free cash flow, the group had less than a year of cash runway — an external estimate, not a company statement, but it underlines the central financial tension of modest, slowly growing revenue set against continuing cash outflow.
Real Milestones, Genuinely Earned
- The presentation of EAF151 data at ASCO placed the company's core imaging metric in front of the world's largest oncology audience within a rigorously designed, cooperative-group trial — independent, prospective validation that carries genuine technical weight.
- The reopening of the gallium maltolate Expanded Access Programme, on the back of first-in-human safety and survival signals, is a second milestone, albeit more speculative — expanded access is not the same as marketing approval.
- The Kirkstall grant selection links the group to the animal-free testing agenda and to an academic partner.
- The company also completed a sub-division of its share capital, a mechanical change that doesn't by itself create or destroy value.
A Genuinely Favourable Sector, Contested by Bigger Players
The sector context is favourable, which is part of what makes the company interesting and part of what makes it easy to over-hype. Quantitative and AI-assisted analysis of medical images is one of the most active areas of health technology, with standardised, vendor-neutral biomarkers prized precisely because they allow results to be compared across scanners, sites, and trials.
Brain cancer is one of the highest-need areas in all of oncology. Glioblastoma, the most common aggressive adult brain tumour, is associated with a median survival typically quoted at little more than a year. Progress has been slow and hard-won, and the blood-brain barrier makes both drug delivery and treatment monitoring unusually difficult. In each of the company's areas, however, the addressable market is contested by far larger and better-funded companies, academic groups, and imaging-equipment manufacturers. A strong theme is not the same as a defensible franchise.
What Could Move the Story Forward
The most immediate catalyst is commercial conversion of the EAF151 validation: signed agreements with trial sponsors, contract research organisations, or distribution partners that turn scientific credibility into recurring software and services revenue. Because the company has framed this as achievable within existing infrastructure, even modest contract wins could move the needle on a revenue base this small.
A second catalyst is progression of gallium maltolate — advancement towards a formal Phase 2 trial, further data, or a licensing arrangement that offloads development cost would each be significant. Any strengthening of the balance sheet on non-dilutive or lightly dilutive terms, or evidence of a clear path to breakeven, would itself be a catalyst, since it would reduce the funding overhang that currently shadows the equity.
The Funding Question Behind Everything
For a company of this size, funding is arguably the decisive variable. A group that's losing money, holds a small cash balance, and has ambitions in both clinical development and commercialisation will, in most scenarios, need to raise capital at some point. Historically, the listed vehicle has used instruments such as convertible loan notes and equity placings to fund itself.
The practical consequence for existing shareholders is dilution risk. Raising equity at a depressed share price, or issuing convertible instruments, increases the number of shares in issue and can transfer value away from current holders, particularly if done from a position of weakness. A concentrated shareholder register cuts both ways: a supportive large holder can provide funding continuity, but it can also reduce free float and liquidity.
Conclusion
Imaging Biometrics is a small, complex company whose story is genuinely more interesting than its size would suggest. It owns a validated imaging technology addressing one of oncology's hardest problems, a laboratory-tools business aligned with the move away from animal testing, and a drug asset that has defied its own earlier deprioritisation with encouraging early data. Those aren't the ingredients of a pure hype stock.
Yet the same company is loss-making, sub-scale, and, on external estimates, tight on cash, with a concentrated register, thin liquidity, and an evident funding overhang. The gap between the ambition of the science and the capacity of the balance sheet is wide, and closing it will require either commercial traction or capital, most likely both. The neutral, fact-based reading is neither a breakthrough foretold nor a false dawn debunked, but an early-stage, high-risk situation in which the technical evidence is running ahead of the financial evidence.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...